PDO异种移植模型在肿瘤精准化治疗研究中的应用进展  

Progress in application of patient-derived organoid xenograft model in cancer precision therapy

作　　者：邢燕子 赵菊梅[1] 师长宏 XING Yanzi;ZHAO Jumei;SHI Changhong(Medical College of Yan’an University,Yan’an 716000,China;Laboratory Animal Center,the Air Force Medical University,Xi’an 710032,China)

机构地区：[1]延安大学基础医学院,陕西延安716000 [2]空军军医大学实验动物中心,西安710032

出　　处：《中国实验动物学报》2025年第1期99-107,共9页Acta Laboratorium Animalis Scientia Sinica

基　　金：国家自然科学基金(32070532,32270566)。

摘　　要：精准化治疗已成为现代医疗的重要手段,其目标是根据患者的特征进行个体化治疗。精准化治疗的成功发展依赖于临床前肿瘤模型的应用。病患来源的肿瘤类器官(patient-derived organoids,PDO)异种移植模型结合了体外PDO模型和体内人源肿瘤异种移植(patient-derived tumor xenograft,PDX)模型的特点,不仅能维持原始肿瘤的异质性,还具有体外大规模培养、高通量药物筛选和体内药物敏感性测试的优点,是一种创新性、精准化的临床前疾病模型。本文综述了PDO异种移植模型的基本特征,分析了其构建方法及影响因素,重点探讨了其在肿瘤精准化治疗中的应用,以期为肿瘤患者个体化治疗提供可靠的临床前实验工具。Precision therapy has become an important approach in modern medicine,with the goal of providing individualized treatment according to the characteristics of individual patients.The successful development of precision medicine depends on the application of preclinical cancer models.Patient-derived organoid(PDO)xenograft models display characteristics of both PDO models and in vivo patient-derived tumor xenograft models.This type of model can not only maintain the heterogeneity of the original tumor,but also has additional advantages,such as large-scale cultivation,high-throughput drug screening in vitro and drug sensitivity testing in vivo.It is an innovative,precise preclinical disease model.In this review,we summarize the basic characteristics of the PDO xenograft model,analyze its construction method and influencing factors,further discuss its application in precision therapy,with the aim of providing a reliable preclinical experimental tool for individualized cancer treatment.

关 键 词：病患来源的肿瘤类器官 异种移植 精准治疗 肿瘤异质性 药物敏感性 

分 类 号：Q95-33[生物学—动物学]